Annual report pursuant to Section 13 and 15(d)

Segment Information (Tables)

v3.6.0.2
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2016
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands):
 
 
 
Dermatology
 
Pharmaceutical and
 
 
 
 
 
 
 
Products
 
Biotechnology
 
 
 
 
 
Year Ended December 31, 2016
 
Sales
 
Product Development
 
National
 
Consolidated
 
Net Revenue
 
$
3,587
 
$
2,570
 
$
10,323
 
$
16,480
 
Direct cost of goods
 
 
(790)
 
 
-
 
 
-
 
 
(790)
 
Sales and marketing costs
 
 
(5,774)
 
 
-
 
 
-
 
 
(5,774)
 
Research and development
 
 
-
 
 
(35,134)
 
 
-
 
 
(35,134)
 
General and administrative
 
 
(1,474)
 
 
(26,755)
 
 
-
 
 
(28,229)
 
National expenses
 
 
 
 
 
 
 
 
(11,754)
 
 
(11,754)
 
Segment loss from operations
 
$
(4,451)
 
$
(59,319)
 
$
(1,431)
 
$
(65,201)
 
Segment assets
 
$
4,469
 
$
115,145
 
$
38,220
 
$
157,834
 
 
 
 
Dermatology
 
Pharmaceutical and
 
 
 
 
 
 
 
Products
 
Biotechnology
 
 
 
 
 
Year Ended December 31, 2015
 
Sales
 
Product Development
 
National
 
Consolidated
 
Net Revenue
 
$
273
 
$
590
 
$
-
 
$
863
 
Direct cost of goods
 
 
- )
 
 
-
 
 
-
 
 
- )
 
Sales and marketing costs
 
 
(2,850)
 
 
-
 
 
-
 
 
(2,850)
 
Research and development
 
 
-
 
 
(29,810)
 
 
-
 
 
(29,810)
 
General and administrative
 
 
(1,682)
 
 
(17,052)
 
 
-
 
 
(18,734)
 
Segment loss from operations
 
$
(4,259)
 
$
(46,272)
 
$
-
 
$
(50,531)
 
Segment assets
 
$
1,965
 
$
116,542
 
$
-
 
$
118,610